Sinzen Medtech Secures Tens of Millions Yuan Series A Financing to Build Innovative Ecosystem for Multi-DOF Endoscopic & Electrosurgical Devices

Shanghai Sinzen Medtech Co., Ltd. has recently completed a Series A financing of tens of millions of yuan. The round was led by Ennovation Venture, with existing shareholder Fong Capital Partners continuing to participate. The funds will be allocated to the expansion of its R&D and production base, commercial promotion, and FDA & CE registration for overseas expansion.

Founded in May 2020 and headquartered in Shanghai, Sinzen Medtech is a start-up focused on original surgical product technologies in China. Leveraging its Me-better original technologies covering multi-degree-of-freedom mechanical control, innovative energy solutions and digitalization, the company is committed to building an innovative surgical treatment ecosystem encompassing open surgery, laparoscopy, endoscopy and percutaneous access.

Sinzen Medtech focuses on the general surgery track, covering laparoscopic procedures in thoracic surgery, general surgery, urology and gynecology with an annual surgical volume of over 4 million cases, as well as orthopedic surgeries including trauma, joint and spine procedures with an annual volume of more than 5 million cases. Many Fortune 500 companies have emerged in these sectors, including global players such as Johnson & Johnson, Medtronic, BD, Stryker and B. Braun.

Currently, Sinzen Medtech has two exclusive products that have entered the commercialization stage, while the remaining series of products are at different stages of registration and development.

Sinzen Medtech’s Zhishui single‑use mono‑and bipolar electrodes are positioned for hemostasis of muscular and bone marrow wound surfaces in orthopedic procedures (trauma, joint, spine and bone tumor surgery), as well as the management of extensive diffuse parenchymal bleeding during hepatic surgery. In 2025, the product was selected for the Innovative Medical Device Product Application Demonstration project funded by the Shanghai Science and Technology Commission. Led by the Department of Orthopedics of Shanghai Sixth People’s Hospital, the project unites Zhongshan Hospital, Huashan Hospital, Shanghai First People’s Hospital, Xinhua Hospital and other top medical institutions. Over a three‑year period, it will carry out clinical application research on trauma, joint, spine and bone tumor procedures, formulate expert consensus, and support the development of the second‑generation product.

In addition, the Zhishui product has participated in the high-frequency electrosurgical device alliance centralized procurement covering 29 provincial regions and successfully been selected as a winning bidder. Its integrated monopolar and bipolar energy technology makes Sinzen Medtech the original innovator of the combined mono-bipolar technical item in this centralized procurement. It is also one of the rare centralized procurement categories defined by a domestic Chinese enterprise, breaking the long-standing monopoly of European and American companies in defining procurement classification standards. Products featuring the combined mono-bipolar design remain rare among equivalent varieties. They boast remarkable differentiated advantages in the second-round volume declaration and new hospital admission, with access thresholds greatly lowered, enabling broader patient access to medical services.

In early 2026, Sinzen Medtech launched its second globally exclusive product —the SurRotate single‑use multi‑joint endoscopic suturing device, featuring 4 degrees of freedom (4 DOF) and dual locking of the jaw and joints. It has successfully completed animal studies of urethrovesical reconstruction in laparoscopic posterior approach radical prostatectomy, as well as human laparoscopic ureterectomy and reconstruction, breaking the monopoly of surgical robots in suturing and reconstruction within this field.

Precisely Solve Three Major Clinical Pain Points:

• Traditional endoscopic straight needle holders cannot bend, making it difficult to reach the target operation site in narrow spaces. The long learning curve restricts the development of endoscopic surgery.

• Robotic-assisted laparoscopic surgery systems cannot cover all operating rooms in large hospitals or extend to grassroots-level hospitals in the short term due to factors such as licensing and cost.

• Overseas similar products have problems such as low cost-performance, inability to charge, and inconvenient operation.

Original Design & Core Competitive Advantages Worldwide：

• It adopts four-degree-of-freedom motion that enables wrist and fingertip control of the tip’s bending, rotation and opening/closing. Combined with dual locking of the jaw and joint, the device can rapidly reach any surgical site to perform multi-angle suturing and knotting. It features a proprietary index-finger needle-rotating suturing method. Surgeons can complete suturing simply by rotating the instrument tip with fingers, offering greater ease and precision compared with traditional wrist-rotation suturing.

• Designed as a single-use disposable device to reduce infection risks and eliminate the need for additional equipment procurement.

• Compact and lightweight, it fits seamlessly into any operating room with high portability and easy operator training.

• Provides force feedback for enhanced procedural safety.

• Compatible with existing endoscopic imaging systems; optimized for next-generation reduced-port and single-port laparoscopic procedures.

• Widely applicable to thoracoscopic and laparoscopic surgeries across multiple departments, including urology, general surgery, thoracic surgery and gynecology.

As a billable single-use medical consumable for clinical settings, the SurRotate  single-use multi-joint endoscopic suturing device has completed provincial and municipal listing across China, enabling rapid clinical adoption and medical billing. In terms of intellectual property, the company has obtained invention patents in China, the United States, Europe, Japan, South Korea and other regions, as well as FDA certification in the U.S. Its global IP layout covers major medical markets worldwide, laying a solid foundation for the product’s domestic and international commercialization.

Furthermore, Artisential by Livsmed (a global peer in the same segment) has seen rapid growth in worldwide sales. The company listed on the Korean IPO in December 2025, with a current valuation of 1.6 trillion KRW (approximately 8 billion RMB). A 2026 publication of a 2022–2024 Korean multicenter comparative study involving 740 cases of low rectal cancer surgery demonstrated that intra-operative use of the Artisential multi‑joint instrument achieved equivalent therapeutic outcomes compared to surgical robots, but with shorter operation time (126 min vs. 153 min) and only 20% of the cost of robotic systems. U.S.-based FlexDex Surgical, after securing a $13 million investment from Johnson & Johnson in 2022, was acquired by LivsMed (Korea) in January 2026. Overall, the commercial and evidence‑based medical feasibility of global multi‑joint endoscopic surgical instruments has been preliminarily validated.

Sinzen Medtech is set to officially launch its SurRotate single-use multi-joint endoscopic monopolar electrohook in the second half of 2026. As the world’s only manual 3-degree-of-freedom device, it is tailored for cutting and hemostasis in laparoscopic procedures of thoracic surgery, breast surgery and thyroid surgery. Meanwhile, Zhipao, the world’s first disposable handheld portable surgical robot, has completed R&D finalization and its first animal experiment, with operational performance further approaching that of traditional surgical robots. Sinzen Medtech keeps advancing the R&D of more original products. We sincerely invite distributors and industry partners to jointly explore the market and create win-win prospects for the future.